Mesenchymal stromal cell–secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23-expressing cells

Paola Vinci, Antonio Bastone, Silvia Schiarea, Claudia Cappuzzello, Annalisa Del Prete, Erica Dander, Andrea Biondi, Giovanna D'Amico

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Mesenchymal stromal cells (MSCs) are multipotent cells characterized by broad immunomodulatory properties exploited for the treatment of inflammatory disorders. However, the efficacy of MSC-based therapy is highly variable and tightly linked to MSC culture conditions and treatment schedule. Thus, the identification of novel key molecules regulating MSC immunomodulatory activities in vivo might constitute a crucial step toward the optimization of currently available clinical protocols. In this regard, herein, we sought to determine whether the newly identified chemotactic protein, chemerin, plays a role in MSC-mediated regulation of inflammation. Methods Chemerin production by human MSCs was investigated under different culture conditions using enzyme-linked immunosorbent assay (ELISA). After purification, MSC-secreted chemerin was identified using mass spectrometry analysis and the biological activity of secreted isoforms was evaluated using migration assay. Results Bone marrow–derived MSCs secrete chemerin and express its receptors ChemR23 and CCRL2. Chemerin production is dependent on culture conditions and increases upon stimulation with inflammatory cytokines. In particular, platelet lysate (PL)-MSCs produce higher levels of chemerin compared with fetal bovine serum (FBS)-MSCs. Furthermore, chemerin is secreted by MSCs as an inactive precursor, which can be converted into its active form by exogenous chemerin-activating serine and cysteine proteases. Discussion Our data indicate that, in response to various inflammatory stimuli, MSCs secrete high amounts of inactive chemerin, which can then be activated by inflammation-induced tissue proteases. In light of these initial findings, we propose that further analysis of chemerin functions in vivo might constitute a crucial step toward optimizing MSC-based therapy for inflammatory diseases.

Original languageEnglish
Pages (from-to)200-210
Number of pages11
JournalCytotherapy
Volume19
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Mesenchymal Stromal Cells
Cell- and Tissue-Based Therapy
Inflammation
Cysteine Proteases
Serine Proteases
Clinical Protocols
Mass Spectrometry
Appointments and Schedules
Protein Isoforms
Peptide Hydrolases
Blood Platelets
Cell Culture Techniques
Enzyme-Linked Immunosorbent Assay
Cytokines

Keywords

  • chemerin
  • ChemR23 receptor
  • immunomodulation
  • mesenchymal stromal cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Cite this

Mesenchymal stromal cell–secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23-expressing cells. / Vinci, Paola; Bastone, Antonio; Schiarea, Silvia; Cappuzzello, Claudia; Del Prete, Annalisa; Dander, Erica; Biondi, Andrea; D'Amico, Giovanna.

In: Cytotherapy, Vol. 19, No. 2, 01.02.2017, p. 200-210.

Research output: Contribution to journalArticle

Vinci, Paola ; Bastone, Antonio ; Schiarea, Silvia ; Cappuzzello, Claudia ; Del Prete, Annalisa ; Dander, Erica ; Biondi, Andrea ; D'Amico, Giovanna. / Mesenchymal stromal cell–secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23-expressing cells. In: Cytotherapy. 2017 ; Vol. 19, No. 2. pp. 200-210.
@article{fe8e3e0ed6a64534936bf46ec0a0f6fe,
title = "Mesenchymal stromal cell–secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23-expressing cells",
abstract = "Background Mesenchymal stromal cells (MSCs) are multipotent cells characterized by broad immunomodulatory properties exploited for the treatment of inflammatory disorders. However, the efficacy of MSC-based therapy is highly variable and tightly linked to MSC culture conditions and treatment schedule. Thus, the identification of novel key molecules regulating MSC immunomodulatory activities in vivo might constitute a crucial step toward the optimization of currently available clinical protocols. In this regard, herein, we sought to determine whether the newly identified chemotactic protein, chemerin, plays a role in MSC-mediated regulation of inflammation. Methods Chemerin production by human MSCs was investigated under different culture conditions using enzyme-linked immunosorbent assay (ELISA). After purification, MSC-secreted chemerin was identified using mass spectrometry analysis and the biological activity of secreted isoforms was evaluated using migration assay. Results Bone marrow–derived MSCs secrete chemerin and express its receptors ChemR23 and CCRL2. Chemerin production is dependent on culture conditions and increases upon stimulation with inflammatory cytokines. In particular, platelet lysate (PL)-MSCs produce higher levels of chemerin compared with fetal bovine serum (FBS)-MSCs. Furthermore, chemerin is secreted by MSCs as an inactive precursor, which can be converted into its active form by exogenous chemerin-activating serine and cysteine proteases. Discussion Our data indicate that, in response to various inflammatory stimuli, MSCs secrete high amounts of inactive chemerin, which can then be activated by inflammation-induced tissue proteases. In light of these initial findings, we propose that further analysis of chemerin functions in vivo might constitute a crucial step toward optimizing MSC-based therapy for inflammatory diseases.",
keywords = "chemerin, ChemR23 receptor, immunomodulation, mesenchymal stromal cells",
author = "Paola Vinci and Antonio Bastone and Silvia Schiarea and Claudia Cappuzzello and {Del Prete}, Annalisa and Erica Dander and Andrea Biondi and Giovanna D'Amico",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.jcyt.2016.11.006",
language = "English",
volume = "19",
pages = "200--210",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Mesenchymal stromal cell–secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23-expressing cells

AU - Vinci, Paola

AU - Bastone, Antonio

AU - Schiarea, Silvia

AU - Cappuzzello, Claudia

AU - Del Prete, Annalisa

AU - Dander, Erica

AU - Biondi, Andrea

AU - D'Amico, Giovanna

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background Mesenchymal stromal cells (MSCs) are multipotent cells characterized by broad immunomodulatory properties exploited for the treatment of inflammatory disorders. However, the efficacy of MSC-based therapy is highly variable and tightly linked to MSC culture conditions and treatment schedule. Thus, the identification of novel key molecules regulating MSC immunomodulatory activities in vivo might constitute a crucial step toward the optimization of currently available clinical protocols. In this regard, herein, we sought to determine whether the newly identified chemotactic protein, chemerin, plays a role in MSC-mediated regulation of inflammation. Methods Chemerin production by human MSCs was investigated under different culture conditions using enzyme-linked immunosorbent assay (ELISA). After purification, MSC-secreted chemerin was identified using mass spectrometry analysis and the biological activity of secreted isoforms was evaluated using migration assay. Results Bone marrow–derived MSCs secrete chemerin and express its receptors ChemR23 and CCRL2. Chemerin production is dependent on culture conditions and increases upon stimulation with inflammatory cytokines. In particular, platelet lysate (PL)-MSCs produce higher levels of chemerin compared with fetal bovine serum (FBS)-MSCs. Furthermore, chemerin is secreted by MSCs as an inactive precursor, which can be converted into its active form by exogenous chemerin-activating serine and cysteine proteases. Discussion Our data indicate that, in response to various inflammatory stimuli, MSCs secrete high amounts of inactive chemerin, which can then be activated by inflammation-induced tissue proteases. In light of these initial findings, we propose that further analysis of chemerin functions in vivo might constitute a crucial step toward optimizing MSC-based therapy for inflammatory diseases.

AB - Background Mesenchymal stromal cells (MSCs) are multipotent cells characterized by broad immunomodulatory properties exploited for the treatment of inflammatory disorders. However, the efficacy of MSC-based therapy is highly variable and tightly linked to MSC culture conditions and treatment schedule. Thus, the identification of novel key molecules regulating MSC immunomodulatory activities in vivo might constitute a crucial step toward the optimization of currently available clinical protocols. In this regard, herein, we sought to determine whether the newly identified chemotactic protein, chemerin, plays a role in MSC-mediated regulation of inflammation. Methods Chemerin production by human MSCs was investigated under different culture conditions using enzyme-linked immunosorbent assay (ELISA). After purification, MSC-secreted chemerin was identified using mass spectrometry analysis and the biological activity of secreted isoforms was evaluated using migration assay. Results Bone marrow–derived MSCs secrete chemerin and express its receptors ChemR23 and CCRL2. Chemerin production is dependent on culture conditions and increases upon stimulation with inflammatory cytokines. In particular, platelet lysate (PL)-MSCs produce higher levels of chemerin compared with fetal bovine serum (FBS)-MSCs. Furthermore, chemerin is secreted by MSCs as an inactive precursor, which can be converted into its active form by exogenous chemerin-activating serine and cysteine proteases. Discussion Our data indicate that, in response to various inflammatory stimuli, MSCs secrete high amounts of inactive chemerin, which can then be activated by inflammation-induced tissue proteases. In light of these initial findings, we propose that further analysis of chemerin functions in vivo might constitute a crucial step toward optimizing MSC-based therapy for inflammatory diseases.

KW - chemerin

KW - ChemR23 receptor

KW - immunomodulation

KW - mesenchymal stromal cells

UR - http://www.scopus.com/inward/record.url?scp=85007579702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007579702&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2016.11.006

DO - 10.1016/j.jcyt.2016.11.006

M3 - Article

AN - SCOPUS:85007579702

VL - 19

SP - 200

EP - 210

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 2

ER -